Also of interest to the original post is a summary of the published scientific literature on bufotenin's activity in man:
(As has been mentioned, the frequent use of bufotenin salts limits the applicability of some of these findings to the actual use of the drug by typical routes (intranasal, vaporized, etc. administration of the free-base).
Fabing & Hawkins (1955)
These two have the dubious honor of having been the first to explore bufotenine's activity. They injected it intravenously into four inmates at the Ohio State Penitentiary, in doses ranging up to 16 mg of bufotenine creatinine sulfate. The higher doses in this study caused the subjects faces to turn "the color of an egglant." These subjects apparently also experienced minor short-duration visual phenomena, leading Fabing & Hawkins to classify the drug as "hallucinogenic". (Fabing & Hawkins 1956, Ott 1996)
Isbell (1955)
Working under the auspices of the CIA's infamous project MKULTRA, Isbell administered both bufotenin and cohoba snuff to inmates at the Lexington, Kentucky Federal Narcotics Farm (at this facility, nominally a drug rehab center, incarcerated addicts were offered heroin in exchange for cooperation in the experiments). The snuff was found to be inactive at doses up to a gram (the quality of the snuff is unknown, as this report comes secondhand through Turner and Merliss). Doses of up to 40 mg of bufotenine creatine sulfate were found to be inactive when administered intranasally. With 10-12.5 mg of the same salt administered intramuscularly, subjects experienced "visual hallucinations... a play of colors, lights, and patterns." (Turner & Merliss 1959, Ott 1996).
Turner & Merliss (1959)
Having the leisure of captive subjects in a New York mental institution, Turner and Merliss investigated the effects of both bufotenin and DMT in 14 schizophrenics (their trials with the latter drug will be relevant to the discussion of bufotenin's reported toxicity). They reported dramatic physical symptoms following the intravenous administration of 10 mg bufotenin.
It must be recalled that the subjects in these trials were almost certainly on other medications which could have played a role. In some of the cases, bufotenin injections were administered as "[the 'patients'] were coming out of insulin coma or following EST" (electroshock therapy). In their own words, "each of these injections almost proved fatal in small amounts (between 2.5 and 5.0 mg)," with cessation of breathing and the developement of a "plum-colored" face. They note that "the patients become frightened to an extreme degree," which prompts Ott to wonders "whether this 'paranoia' may have conttributed to their continued incarceration and 'treatment' for 'schizophrenia'."
After finsihing their work with bufotenin, Turner and Merliss concluded that bufotenine was not capable of producing the snuff intoxication.
Next, dynamic duo went on to experiment with the human effects of DMT, finding it quite active when 25 mg or more was administered intravenously. In one case, a female patient suffered cardiac arrest and nearly died after the intravenous administration of 40 mg DMT (
not bufotenin, which only caused respiratory arrest). This has been reported mistakenly in the literature as a case of "bufotenine toxicity". Based on the work of Dr. Rick Strassman, it would appear that interactions with other medications must have played a role in this instance. (Turner & Merliss 1959, Ott 1996).
Bonhour et al (1967)
Intravenous injection of 12-16 mg bufotenin (again as a water-soluble salt) essentially confirmed the fidings of Fabing & Hawkins. (Bonhour et al 1967, Ott 1996).
In the bufotenin entry of TiHKAL, Dr. Shulgin presents a couple of quotes from patients exemplifying the somatic and visual effects typically encountered with lower-dose IV administration. At higher doses, the unpleasant somatic effects from intravenous administration appear to largely drown out the psychoactive effects.
Quote:(with 4 mg, intravenously, over a 3 minute period) "During the injection, I first felt a burning sensation in my face, then a load pressing down from above, and then a numbness of the entire body. I saw red and black spots -- a vivid orange-red -- moving around. Apparently my purplish face color lasted some 15 minutes, well after my visual things had disappeared."
Quote:(with 8 mg, intravenously, over a 3 minute period) "I became lightheaded as soon as the injection started, and then my face turned purple and I became nauseated and I felt I couldn't breathe. I see white, straight lines with a black background. I can't trace a pattern. Now there are red, green and yellow dots, very bright like they were made out of fluorescent cloth, moving like blood cells through capillaries, weaving in and out of the white lines. I another two minutes, everything was pretty much gone."
This was essentially the state of the inquiry into bufotenin's activity prior to the pbulication of Jonathan Ott's landmark
Pharmanopo Psychonautics. Shulgin summed up the state of the literature with respect to the activity in bufotenin in the late 1990s:
Quote:Some clinicians demand that the compound is unquestionably a psychotomimetic and it must be catalogued right up there along with LSD and psilocybin. Others, equally sincere, present human trials that suggest only peripheral toxicity and conclude that there is no central action to be seen. And there are many who state that there are no effects for it at all, either inside or outside the CNS. The psychopharmacological status of bufotenine... may be essentially unanswerable... At the bottom line, I do not really know if bufotenine is a psychedelic drug. Maybe yes and maybe no.
However, he also notes a very compelling bit of evidence for bufotenin's role in the psychoactivity of Anadenanthera snuffs:
Quote:A study of the use of the seeds of a South American legume, Anadenanthera colubrina var. Cebil by the Argentine Shamans in Chaco Central, shows then to be dramatically psychedelic. And yet, extremely sophisticated spectroscopic analysis has shown them to contain bufotenine and only bufotenine as their alkaloid component.
Referencing this fact (and the bulk of older literature which confirms bufotenin to be the primary alkaloid in the seeds), Ott points to psychonautic bioassays by himself, CM Torres, Christian Raetsch, Pages Laraya, and Castillo, which clearly indicate the seeds to be a psychoptic (psychoactive visonary) agent. He then details his experiences with a range of doses by various routes of administration, both in the presence and absence of an MAOI (read the article if you haven't). This work seems to definitively establish that the concerning somatic effects of IV bufotenin salts don't appear to be so much of an issue when administering the free-base orally, buccally, parenterally as vapor, or intrarectally.
Ott's bioassays would firmly establish bufotenine as the chemical reponsible for the psychoptic effects of Anadenanthera snuffs, were it not for the tremendous disparity between the timeline of his intranasal bufotenin freebase experiences (peaking around 35 minutes in), compared to SWIM and many others' experiences with Anadenanthera snuffs (peaking 3 to 5 minutes in).
And so that's how it stands today: Anadenanthera seeds are without a doubt a psychoptic agent. Bufotenin is without a doubt a psychoptic agent. All the literature suggest bufotenin is the only alkaloid present in the seeds at a high enough concentration to account for psychoactive effects. And yet, the fundamental question, whether bufotenin is solely responsible for the psychoptic effects of the seed snuff, has still not been answered to a satisfactory extent.
Kind of ironic, when we consider the words of Safford, in his 1916 article providing a definitive botanical identification of the source of the snuff:
Quote:The most remarkable fact associated with this narcotic [sic] is that... the source of its intoxicating properties still remains unknown.